ERBB2 and breast carcinoma: In patients with luminal B breast cancer who did not receive NAC, adjuvant chemotherapy was more frequently used in the HER2 + luminal B breast cancer group, and the incidence of distant metastasis and death were higher in the HER2− luminal B breast cancer group (P = .005, 0.036) (Table 3) (Fig. 3).